Answers are grounded in this paper and cite their sources.
Platelet factor (PF4), connective tissue activating peptide III (CTAP-III) and two fragments of C3a may be potential protein biomarkers of pediatric ALL and used to distinguish pediatric ALL patients from healthy controls and pediatric AML patients. Further studies with additional populations or using pre-diagnostic sera are needed to confirm the importance of these findings as diagnostic markers of pediatric ALL.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: